Scrub Typhus Management: Azithromycin, Doxycycline, or Both?

Scrub typhus, caused by Orientia tsutsugamushi, is a mite-borne febrile illness endemic to South and Southeast Asia. It presents with fever, rash, eschar, and in severe cases, multi-organ dysfunction. Timely antibiotic therapy is essential, yet the choice between doxycycline, azithromycin, or combination therapy remains a subject of clinical debate. Traditionally, doxycycline has been the mainstay of treatment, known for its rapid fever resolution and broad efficacy in adults. However, its use in young children and pregnant women is with concerns about dental staining and teratogenicity. This has led to increased interest in azithromycin, a macrolide antibiotic with a safer profile in these populations. A randomized controlled trial from AIIMS Bhubaneswar, published in in 2022, directly compared these two drugs in children.[1] The study enrolled pediatric patients with confirmed scrub typhus and randomized them to receive either azithromycin or doxycycline for 5 days. The results showed comparable efficacy in terms of fever resolution and clinical recovery, with azithromycin demonstrating better tolerability and fewer gastrointestinal side effects. This supports azithromycin as a viable first-line option in pediatric cases. However, not all findings favor azithromycin. A 2021 study from South India reported treatment failure in children receiving azithromycin, necessitating a switch to doxycycline.[2] Similarly, a 2022 meta-analysis from PGIMER Chandigarh found higher clinical failure rates with azithromycin, especially in moderate-to-severe cases.[3] These discrepancies suggest that while azithromycin is safer, it may be less potent in certain clinical scenarios or regions with emerging resistance. The role of combination therapy—using both doxycycline and azithromycin—has been explored in severe or refractory cases. The INTREST trial (2023) from Christian Medical College, Vellore, evaluated intravenous administration of both drugs in patients with organ involvement. Combination therapy showed improved outcomes in critically ill patients, though routine use is not recommended due to cost and concerns about antibiotic overuse.[4] Importantly, no confirmed doxycycline resistance has been reported in human cases, though laboratory studies have induced resistance in animal models. Treatment failure with doxycycline is more likely due to delayed presentation or severe disease rather than true microbial resistance. In summary, the management of scrub typhus should be tailored to patient age, disease severity, and regional patterns. Doxycycline remains the gold standard for adults with uncomplicated disease. Azithromycin is a safe and effective alternative in children and pregnant women, particularly for uncomplicated cases. Combination therapy may be reserved for severe or unresponsive presentations.[5] As research continues to evolve, clinicians must balance efficacy, safety, and accessibility—ensuring that treatment decisions are guided by evidence and patient context.[6,7] The debate reflects a broader commitment to personalized care in infectious disease management. Acknowledgement None. Authors contribution MPM conceived the idea, designed the study, drafted the manuscript, and submitted it for publication. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.